Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
VRXA compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
VRXA
Veraxa Biotech AG - Post de-SPAC
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Event sensitivity
Desk
News
Calendar
Saved
Search
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
0.94
▼
−1.53%
· post 0.94
Mkt cap
$13.8M
Revenue
—
Revenue
—
LLY
ELI Lilly & Co
Change
1,360.90
▼
−0.28%
· post 1,358.90
Closed
Nov 6 '26
Mkt cap
$1.2T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Closed
Nov 6 '26
VRXA
Veraxa Biotech AG - Post de-SPAC
vs
LLY
ELI Lilly & Co
0.94
▼
−1.53%
post 0.94
Price
1,360.90
▼
−0.28%
post 1,358.90
$13.8M
Mkt cap
$1.2T
—
Revenue
$24.4B
Q3 FY26
—
Revenue
$65.2B
FY25
Change
Change
VRXA
0.94
▼
−1.53%
vs
LLY
1,360.90
▼
−0.28%
Closed
Nov 6 '26
Event sensitivity
release-day history · min 6 releases
Method
›
Insufficient release history: VRXA.